Amphastar Pharmaceuticals Statistics
Share Statistics
Amphastar Pharmaceuticals has 48.08M shares outstanding. The number of shares has increased by -0.03% in one year.
| Shares Outstanding | 48.08M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -1.22% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 35.79M |
| Failed to Deliver (FTD) Shares | 24.48K |
| FTD / Avg. Volume | 4.98% |
Short Selling Information
The latest short interest is 4.37M, so 9.08% of the outstanding shares have been sold short.
| Short Interest | 4.37M |
| Short % of Shares Out | 9.08% |
| Short % of Float | 12.2% |
| Short Ratio (days to cover) | 9.77 |
Valuation Ratios
The PE ratio is 21.7 and the forward PE ratio is 10.92. Amphastar Pharmaceuticals 's PEG ratio is 0.23.
| PE Ratio | 21.7 |
| Forward PE | 10.92 |
| PS Ratio | 4.63 |
| Forward PS | 2.1 |
| PB Ratio | 4.67 |
| P/FCF Ratio | 20.54 |
| PEG Ratio | 0.23 |
Enterprise Valuation
Amphastar Pharmaceuticals Inc. has an Enterprise Value (EV) of 3.46B.
| EV / Earnings | 25.19 |
| EV / Sales | 5.38 |
| EV / EBITDA | 14.42 |
| EV / EBIT | 17.59 |
| EV / FCF | 23.84 |
Financial Position
The company has a current ratio of 2.17, with a Debt / Equity ratio of 0.98.
| Current Ratio | 2.17 |
| Quick Ratio | 1.7 |
| Debt / Equity | 0.98 |
| Total Debt / Capitalization | 49.38 |
| Cash Flow / Debt | 0.29 |
| Interest Coverage | 7.25 |
Financial Efficiency
Return on equity (ROE) is 0.22% and return on capital (ROIC) is 12.7%.
| Return on Equity (ROE) | 0.22% |
| Return on Assets (ROA) | 0.09% |
| Return on Capital (ROIC) | 12.7% |
| Revenue Per Employee | 365.93K |
| Profits Per Employee | 78.11K |
| Employee Count | 1.76K |
| Asset Turnover | 0.43 |
| Inventory Turnover | 2.77 |
Taxes
| Income Tax | 31.83M |
| Effective Tax Rate | 0.19 |
Stock Price Statistics
The stock price has increased by -30.68% in the last 52 weeks. The beta is 0.82, so Amphastar Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 0.82 |
| 52-Week Price Change | -30.68% |
| 50-Day Moving Average | 42.88 |
| 200-Day Moving Average | 43.41 |
| Relative Strength Index (RSI) | 45 |
| Average Volume (20 Days) | 492.04K |
Income Statement
In the last 12 months, Amphastar Pharmaceuticals had revenue of 644.39M and earned 137.54M in profits. Earnings per share was 2.85.
| Revenue | 644.39M |
| Gross Profit | 351.12M |
| Operating Income | 196.99M |
| Net Income | 137.54M |
| EBITDA | 240.29M |
| EBIT | 196.99M |
| Earnings Per Share (EPS) | 2.85 |
Balance Sheet
The company has 144.30M in cash and 623.64M in debt, giving a net cash position of -479.35M.
| Cash & Cash Equivalents | 144.30M |
| Total Debt | 623.64M |
| Net Cash | -479.35M |
| Retained Earnings | 409.27M |
| Total Assets | 1.55B |
| Working Capital | 386.94M |
Cash Flow
In the last 12 months, operating cash flow was 183.50M and capital expenditures -38.17M, giving a free cash flow of 145.34M.
| Operating Cash Flow | 183.50M |
| Capital Expenditures | -38.17M |
| Free Cash Flow | 145.34M |
| FCF Per Share | 3.01 |
Margins
Gross margin is 54.49%, with operating and profit margins of 30.57% and 21.34%.
| Gross Margin | 54.49% |
| Operating Margin | 30.57% |
| Pretax Margin | 26.59% |
| Profit Margin | 21.34% |
| EBITDA Margin | 37.29% |
| EBIT Margin | 30.57% |
| FCF Margin | 22.55% |
Dividends & Yields
AMPH does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 7.41% |
| FCF Yield | 7.86% |
Analyst Forecast
The average price target for AMPH is $60, which is 56% higher than the current price. The consensus rating is "Buy".
| Price Target | $60 |
| Price Target Difference | 56% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | 2.98 |
| Piotroski F-Score | 7 |